Cargando…

Solid-phase synthesis and pathological evaluation of pyroglutamate amyloid-β(3-42) peptide

Pyroglutamate amyloid-β(3-42) (Aβ(pE3-42)) is an N-terminally truncated and pyroglutamate-modified Aβ peptide retaining highly hydrophobic, amyloidogenic, and neurotoxic properties. In Alzheimer’s disease (AD) patients, Aβ(pE3-42) peptides accumulate into oligomers and induce cellular toxicity and s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Illhwan, Lee, HeeYang, Lee, Donghee, Park, In Wook, Yoon, Soljee, Kim, Hye Yun, Kim, YoungSoo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831997/ https://www.ncbi.nlm.nih.gov/pubmed/36627316 http://dx.doi.org/10.1038/s41598-022-26616-x

Ejemplares similares

Aryloxypropanolamine targets amyloid aggregates and reverses Alzheimer-like phenotypes in Alzheimer mouse models
por: Lee, Hee Yang, et al.
Publicado: (2022)

Plasma pyroglutamate‐modified amyloid beta differentiates amyloid pathology
por: Wang, Pei‐Ning, et al.
Publicado: (2020)

Thioflavin-positive tau aggregates complicating quantification of amyloid plaques in the brain of 5XFAD transgenic mouse model
por: Shin, Jisu, et al.
Publicado: (2021)

Bicine promotes rapid formation of β-sheet-rich amyloid-β fibrils
por: Kim, Hye Yun, et al.
Publicado: (2020)

Quinacrine directly dissociates amyloid plaques in the brain of 5XFAD transgenic mouse model of Alzheimer’s disease
por: Park, Sohui, et al.
Publicado: (2021)

Activity and Architecture of Pyroglutamate-Modified Amyloid-β (Aβ(pE3-42)) Pores
por: Gillman, Alan L., et al.
Publicado: (2014)

Carprofen alleviates Alzheimer-like phenotypes of 5XFAD transgenic mice by targeting the pathological hallmarks induced by amyloid-β aggregation
por: Lee, Donghee, et al.
Publicado: (2023)

Chemical‐Driven Outflow of Dissociated Amyloid Burden from Brain to Blood
por: Lee, Donghee, et al.
Publicado: (2022)

Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy
por: Perez-Garmendia, Roxanna, et al.
Publicado: (2013)

Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1–40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology
por: Michno, Wojciech, et al.
Publicado: (2019)

Chemical‐Driven Outflow of Dissociated Amyloid Burden from Brain to Blood (Adv. Sci. 12/2022)
por: Lee, Donghee, et al.
Publicado: (2022)

Alzheimer's Disease Diagnosis Using Misfolding Proteins in Blood
por: Lee, HeeYang, et al.
Publicado: (2020)

Novel Vaccine against Pathological Pyroglutamate-Modified Amyloid Beta for Prevention of Alzheimer’s Disease
por: Zagorski, Karen, et al.
Publicado: (2023)

Intracellular accumulation of aggregated pyroglutamate amyloid beta: convergence of aging and Aβ pathology at the lysosome
por: De Kimpe, Line, et al.
Publicado: (2012)

An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer’s disease: pyroglutamate amyloid beta
por: Vukicevic, M., et al.
Publicado: (2022)

Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease
por: Moro, Maria Luisa, et al.
Publicado: (2018)

Glycosylated and Succinylated Macrocyclic Lactones with Amyloid-β-Aggregation-Regulating Activity from a Marine Bacillus sp.
por: Cui, Jinsheng, et al.
Publicado: (2023)

Molecular Mechanism of L-Pyroglutamic Acid Interaction with the Human Sour Receptor
por: Eom, Sanung, et al.
Publicado: (2023)

A small molecule Nec-1 directly induces amyloid clearance in the brains of aged APP/PS1 mice
por: Yang, Seung-Hoon, et al.
Publicado: (2019)

Age-dependent inverse correlations in CSF and plasma amyloid-β(1–42) concentrations prior to amyloid plaque deposition in the brain of 3xTg-AD mice
por: Cho, Soo Min, et al.
Publicado: (2016)

Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration
por: Becker, Andreas, et al.
Publicado: (2013)

Role of the Fast Kinetics of Pyroglutamate-Modified Amyloid-β Oligomers in Membrane Binding and Membrane Permeability
por: Lee, Joon, et al.
Publicado: (2014)

Pyroglutamate-modified Aβ(3-42) affects aggregation kinetics of Aβ(1-42) by accelerating primary and secondary pathways
por: Dammers, C., et al.
Publicado: (2017)

Intraneuronal pyroglutamate-Abeta 3–42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model
por: Wirths, Oliver, et al.
Publicado: (2009)

Synergistic Effect on Neurodegeneration by N-Truncated Aβ(4−42) and Pyroglutamate Aβ(3−42) in a Mouse Model of Alzheimer's Disease
por: Lopez-Noguerola, Jose S., et al.
Publicado: (2018)

Metabolic Acidosis Due To Pyroglutamic Acid
por: Serpa, Maria João, et al.
Publicado: (2018)

Flucloxacillin and paracetamol induced pyroglutamic acidosis
por: Zand Irani, Anis, et al.
Publicado: (2021)

Comprehensive Characterization of the Pyroglutamate Amyloid-β Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice
por: Dunkelmann, Tina, et al.
Publicado: (2018)

Correlations of amyloid-β concentrations between CSF and plasma in acute Alzheimer mouse model
por: Cho, Soo Min, et al.
Publicado: (2014)

Modulation of aggregation and structural polymorphisms of β-amyloid fibrils in cellular environments by pyroglutamate-3 variant cross-seeding
por: Cruceta, Letticia, et al.
Publicado: (2023)

Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers
por: Lee, Jinny Claire, et al.
Publicado: (2019)

Purification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR Spectroscopy
por: Dammers, Christina, et al.
Publicado: (2015)

Correlation of pyroglutamate amyloid β and ptau Ser202/Thr205 levels in Alzheimer’s disease and related murine models
por: Neddens, Joerg, et al.
Publicado: (2020)

Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases
por: Wirths, Oliver, et al.
Publicado: (2009)

4,4′-Bipyridine–pyroglutamic acid (1/2)
por: Arman, Hadi D., et al.
Publicado: (2009)

Pyroglutamic Acidosis – An Underrecognised Entity Associated with Acetaminophen Use
por: Ng, Wincy Wing-Sze, et al.
Publicado: (2023)

A novel study on amyloid β peptide 40, 42 and 40/42 ratio in Saudi autistics
por: Al- Ayadhi, Laila Y, et al.
Publicado: (2012)

Solid Lipid Nanoparticles Loading Idebenone Ester with Pyroglutamic Acid: In Vitro Antioxidant Activity and In Vivo Topical Efficacy
por: Montenegro, Lucia, et al.
Publicado: (2018)

RRY Inhibits Amyloid-β(1–42) Peptide Aggregation and Neurotoxicity
por: Sun, Xicui, et al.
Publicado: (2021)

Evaluation of Pharmacokinetic Feasibility of Febuxostat/L-pyroglutamic Acid Cocrystals in Rats and Mice
por: Yu, Jeong-Eun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pecto02aalkrubn2af01j040dl